NASDAQ · KZIA
Healthcare · Biotechnology
$11.19
Up+$0.18 (+1.63%)
Updated Sep 12, 2026, 5:19 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
KZIA closed at $11.19 after 20 trading sessions, down 17.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $11.10 | $11.425 | $10.83 | $11.19 | 340.79K |
| Sep 10, 2026 | $11.75 | $11.75 | $10.83 | $11.01 | 374.29K |
| Sep 9, 2026 | $12.50 | $12.75 | $11.76 | $11.88 | 238.06K |
| Sep 8, 2026 | $12.29 | $12.47 | $11.95 | $12.01 | 158.67K |
| Sep 4, 2026 | $12.00 | $12.62 | $11.765 | $12.31 | 414.45K |
| Sep 3, 2026 | $12.62 | $12.99 | $12.04 | $12.16 | 413.81K |
| Sep 2, 2026 | $12.66 | $13.13 | $12.05 | $12.61 | 360.97K |
| Sep 1, 2026 | $13.69 | $13.69 | $12.27 | $12.63 | 612.2K |
| Aug 31, 2026 | $13.70 | $14.42 | $13.00 | $13.77 | 379.87K |
| Aug 28, 2026 | $15.48 | $15.50 | $13.30 | $13.58 | 1.18M |
| Aug 27, 2026 | $14.67 | $17.18 | $14.67 | $16.90 | 985.9K |
| Aug 26, 2026 | $13.79 | $14.79 | $13.62 | $14.60 | 100.85K |
| Aug 25, 2026 | $13.25 | $13.98 | $13.25 | $13.79 | 92.94K |
| Aug 24, 2026 | $13.36 | $13.4216 | $13.00 | $13.20 | 61.8K |
| Aug 21, 2026 | $13.67 | $13.96 | $13.06 | $13.405 | 148.99K |
| Aug 20, 2026 | $13.96 | $13.97 | $13.44 | $13.67 | 99.56K |
| Aug 19, 2026 | $14.75 | $15.00 | $13.77 | $14.07 | 141.55K |
| Aug 18, 2026 | $13.37 | $14.725 | $13.00 | $14.38 | 161.7K |
| Aug 17, 2026 | $13.35 | $13.7799 | $13.09 | $13.56 | 115.87K |
| Aug 14, 2026 | $13.11 | $13.75 | $12.82 | $13.52 | 142.77K |
The latest Smart Investors Daily articles mentioning KZIA.
KZIA research
Company profile and research snapshot.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | BTIG | Buy | — |
| Sep 1, 2026 | BTIG | Buy | — |
| Aug 13, 2026 | Canaccord Genuity | Buy | — |
| Jul 15, 2026 | BTIG | Buy | — |
| Jul 1, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Jan 30, 2026
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progressionSYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused
Benzinga · Jan 28, 2026
HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $18 price target.
Yahoo · Jan 27, 2026
Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC).
Yahoo · Jan 8, 2026
Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning KZIA.
